Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes.

J Clin Med · 2024 · PMC10816438 · PMID 38256615

Europe PMC DOI

hedged sentence

0.0870

closest p · 1.7× alpha

0.0870

boldest claim

The sentences

marginally significantp = 0.087so close (0.05 < p ≤ 0.1)

After the vildagliptin treatment, a significant decrease in the median HbA1c (from 8.3 to 6.4%) and fasting HOMA-β (from 26.1 to 34.5%), and a marginally significant decrease in the CAVI (from 8.9 to 8.4, p = 0.087) were observed.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.